 | • レポートコード：TPM-NV193 • 出版社/出版日：Transparency Market Research / 2019年10月28日 • レポート形態：英文、PDF、177ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、アテローム性動脈硬化治療薬の世界市場について調べ、アテローム性動脈硬化治療薬の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別（抗血小板薬、コレステロール低下薬、フィブリン酸およびオメガ3脂肪酸誘導体、ベータ遮断薬、アンジオテンシン変換酵素（ACE）阻害薬、カルシウムチャネル遮断薬、利尿薬、その他）分析、流通チャンネル別（小売薬局、病院薬局、オンライン薬局）分析、関連企業情報などをまとめました。 ・アテローム性動脈硬化治療薬の市場概要 ・アテローム性動脈硬化治療薬の市場動向 ・アテローム性動脈硬化治療薬の世界市場規模・予測 ・アテローム性動脈硬化治療薬市場：薬物クラス別（抗血小板薬、コレステロール低下薬、フィブリン酸およびオメガ3脂肪酸誘導体、ベータ遮断薬、アンジオテンシン変換酵素（ACE）阻害薬、カルシウムチャネル遮断薬、利尿薬、その他） ・アテローム性動脈硬化治療薬市場：流通チャンネル別（小売薬局、病院薬局、オンライン薬局） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
Despite the prevalence of diabetes and cholesterol among a wide patient pool, the atherosclerosis drugs market will move at a sluggish CAGR of 2.5% during the forecast period, finds a recently published report by Transparency Market Research (TMR).
This market growth is attributable to the high consumption of cholesterol-lowering drugs by patients to reduce blockages in arteries. A sedentary, yet, demanding lifestyle instigates consumers to opt for quick dietary choices, which will catalyze revenue streams to the atherosclerosis drugs landscape.
To add to that, government initiatives at a global level have played a crucial role in improving the quality of healthcare services and infrastructure, which has been encouraging pharmaceutical companies to develop effective drugs for the treatment of various diseases. The effectiveness of drugs coupled with their easy availability through streamlined distribution channels has been complementing the sales of atherosclerosis drugs. Analyzing the current and the future growth scope, the TMR study opines that, the atherosclerosis drugs market will register a value tantamount to ~US$ 57.4 Bn by 2027.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Atherosclerosis Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases
4.3.1.2. Development of New Treatments
4.3.1.3. Rising Awareness about Cardiovascular Diseases
4.3.2. Restraints
4.3.2.1. Availability of Generic Products
4.3.2.2. Low Diagnostic Rate
4.3.3. Opportunities
4.4. Global Atherosclerosis Drugs Market Analysis and Forecast, 2017–2027
5. Market Outlook
5.1. Clinical Trial Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Brand Analysis
6. Global Atherosclerosis Drugs Market Analysis and Forecast, By Drug Class
6.1. Introduction & Definition
6.1.1. Key Findings / Developments
6.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
6.2.1. Anti-platelet Medications
6.2.2. Cholesterol Lowering Medications
6.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
6.2.4. Beta Blockers
6.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
6.2.6. Calcium Channel Blockers
6.2.7. Diuretics
6.2.8. Others
6.3. Global Atherosclerosis Drugs Market Attractiveness, by Drug Class
7. Global Atherosclerosis Drugs Market Analysis and Forecast, By Distribution Channel
7.1. Introduction & Definition
7.1.1. Key Findings / Developments
7.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
7.2.1. Retail Pharmacies
7.2.2. Hospital Pharmacies
7.2.3. Online Pharmacies
7.3. Global Atherosclerosis Drugs Market Attractiveness, by Distribution Channel
8. Global Atherosclerosis Drugs Market Analysis and Forecast, By Region
8.1. Key Findings
8.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Atherosclerosis Drugs Market Attractiveness, by region
9. North America Atherosclerosis Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
9.2.1. Anti-platelet Medications
9.2.2. Cholesterol Lowering Medications
9.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
9.2.4. Beta Blockers
9.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
9.2.6. Calcium Channel Blockers
9.2.7. Diuretics
9.2.8. Others
9.3. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Online Pharmacies
9.4. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Atherosclerosis Drugs Market Attractiveness
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Atherosclerosis Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
10.2.1. Anti-platelet Medications
10.2.2. Cholesterol Lowering Medications
10.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
10.2.4. Beta Blockers
10.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
10.2.6. Calcium Channel Blockers
10.2.7. Diuretics
10.2.8. Others
10.3. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
10.3.1. Retail Pharmacies
10.3.2. Hospital Pharmacies
10.3.3. Online Pharmacies
10.4. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country Sub/region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Atherosclerosis Drugs Market Attractiveness
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Atherosclerosis Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
11.2.1. Anti-platelet Medications
11.2.2. Cholesterol lowering medications
11.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
11.2.4. Beta blockers
11.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
11.2.6. Calcium Channel Blockers
11.2.7. Diuretics
11.2.8. Others
11.3. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
11.3.1. Retail Pharmacies
11.3.2. Hospital Pharmacies
11.3.3. Online Pharmacies
11.4. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Atherosclerosis Drugs Market Attractiveness
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Atherosclerosis Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
12.2.1. Anti-platelet Medications
12.2.2. Cholesterol Lowering Medications
12.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
12.2.4. Beta blockers
12.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
12.2.6. Calcium Channel Blockers
12.2.7. Diuretics
12.2.8. Others
12.3. Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
12.3.1. Retail Pharmacies
12.3.2. Hospital Pharmacies
12.3.3. Online Pharmacies
12.4. Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Atherosclerosis Drugs Market Attractiveness
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Atherosclerosis Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
13.2.1. Anti-platelet medications
13.2.2. Cholesterol Lowering Medications
13.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
13.2.4. Beta blockers
13.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
13.2.6. Calcium Channel Blockers
13.2.7. Diuretics
13.2.8. Others
13.3. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
13.3.1. Retail Pharmacies
13.3.2. Hospital Pharmacies
13.3.3. Online Pharmacies
13.4. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Atherosclerosis Drugs Market Attractiveness
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Key Company’s Market Ranking Analysis
14.3. Company Profiles
14.3.1. GlaxoSmithKline Plc
14.3.1.1. Company Overview
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Sanofi
14.3.2.1. Company Overview
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Hoffmann-La Roche Ltd
14.3.3.1. Company Overview
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Bayer AG
14.3.4.1. Company Overview
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Novartis AG
14.3.5.1. Company Overview
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Merck & Co., Inc. (Merck Sharp & Dohme Corp)
14.3.6.1. Company Overview
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
14.3.7.1. Company Overview
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Mylan N.V.
14.3.8.1. Company Overview
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Amgen Inc.
14.3.9.1. Company Overview
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. Pfizer, Inc.
14.3.10.1. Company Overview
14.3.10.2. Company Financials
14.3.10.3. Growth Strategies
14.3.10.4. SWOT Analysis